Provided by Tiger Fintech (Singapore) Pte. Ltd.

bluebird bio

3.29
-0.2100-6.00%
Post-market: 3.330.0400+1.22%16:49 EDT
Volume:2.90M
Turnover:9.67M
Market Cap:32.21M
PE:-0.13
High:3.56
Open:3.55
Low:3.28
Close:3.50
Loading ...

BRIEF-Carlyle And Sk Capital Receive All Required Regulatory Approvals To Complete The Acquisition Of Bluebird Bio

Reuters
·
06 May

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

THOMSON REUTERS
·
06 May

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

Business Wire
·
06 May

bluebird bio Inc expected to post a loss of $3.69 a share - Earnings Preview

Reuters
·
05 May

US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies

MT Newswires Live
·
26 Apr

Sui Ecosystem Token Sees Widespread Price Surge, CETUS Up 36% in 24 Hours

Blockbeats
·
25 Apr

JOHNNIE WALKER ESTABLISHES A NEW STANDARD IN DESIGN INNOVATION BY INTRODUCING BLUE LABEL ULTRA, THE WORLD'S LIGHTEST WHISKY BOTTLE

PR Newswire
·
18 Apr

Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid

MT Newswires Live
·
16 Apr

BUZZ-Bluebird Bio falls after Ayrmid fails to give binding offer

Reuters
·
16 Apr

bluebird bio Shares Down 7.9% at $4.12 Premarket After Ayrmid Fails to Give Binding Offer

THOMSON REUTERS
·
16 Apr

BRIEF-Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement

Reuters
·
16 Apr

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Zacks
·
03 Apr

BRIEF-Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar

Reuters
·
02 Apr

Xcellbio: Granted bluebird bio Commercial License, Got Into Supply Agreement for Use of Co's Proprietary Cell Manufacturing Technology, Avatar

THOMSON REUTERS
·
02 Apr